C
지투지바이오
456160KOSDAQ53.0 / 100
Reference Date: 2026-10-23
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Surged 26.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
GTJ Bio is a leading company in microsphere technology for prolonged-release pharmaceuticals, utilizing its InnoLAMP platform to develop drugs for various diseases and offering CDO/CDMO services. Its key products, including GB-7001, GB-5001, and GB-6002, are undergoing clinical trials in collaboration with global pharmaceutical companies, supported by patented technology and large-scale production capabilities that create high entry barriers.
Number of Employees
48people
Average Salary
125.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
11.90Industry Average 1.200.0Point
9.9x industry avg (risky)
ROE
—Industry Average 8.003.5Point
Debt Ratio
3.69Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2024~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼45.0% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼13.4% (1-year basis)
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (19%, downtrend)
Current 41,750Won52-week high 118,80052-week low 22,950
1-month return6.0Point
1m +26.90% (strong rise)
Volume trend6.0Point
Volume surge
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral투자판단관련주요경영사항 (약효지속성 주사제 개발관련 플랫폼평가 계약 체결)2026-10-19